In melanoma, a number of reports indicates that IL-33 promotes anti-tumor immune responses by recruiting and/or activating eosinophils, dendritic cells (DC), type- 2 innate lymphoid cells (ILC2), NK and CD8 T cells in vivo [2–7]. This evidence concerns the gene CD8A and neoplasm.